Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Identifieur interne : 002A28 ( Main/Merge ); précédent : 002A27; suivant : 002A29Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Auteurs : Muki S. Shey [Afrique du Sud] ; Eugene J. Kongnyuy ; Samuel M. Alobwede ; Charles Shey WiysongeSource :
- The Cochrane database of systematic reviews [ 1469-493X ] ; 2013.
Descripteurs français
- KwdFr :
- Agents antiVIH (effets indésirables), Agents antiVIH (usage thérapeutique), Association médicamenteuse, Benzoxazines (usage thérapeutique), Didéoxynucléosides (usage thérapeutique), Essais contrôlés randomisés comme sujet, Humains, Infections à VIH (traitement médicamenteux), Lamivudine (effets indésirables), Lamivudine (usage thérapeutique), Nelfinavir (usage thérapeutique), Oligopeptides (usage thérapeutique), Pyridines (usage thérapeutique), Sulfate d'atazanavir, Syndrome d'immunodéficience acquise (traitement médicamenteux), Zidovudine (effets indésirables), Zidovudine (usage thérapeutique).
- MESH :
- effets indésirables : Agents antiVIH, Lamivudine, Zidovudine.
- traitement médicamenteux : Infections à VIH, Syndrome d'immunodéficience acquise.
- usage thérapeutique : Agents antiVIH, Benzoxazines, Didéoxynucléosides, Lamivudine, Nelfinavir, Oligopeptides, Pyridines, Zidovudine.
- Association médicamenteuse, Essais contrôlés randomisés comme sujet, Humains, Sulfate d'atazanavir.
English descriptors
- KwdEn :
- Acquired Immunodeficiency Syndrome (drug therapy), Anti-HIV Agents (adverse effects), Anti-HIV Agents (therapeutic use), Atazanavir Sulfate, Benzoxazines (therapeutic use), Dideoxynucleosides (therapeutic use), Drug Combinations, HIV Infections (drug therapy), Humans, Lamivudine (adverse effects), Lamivudine (therapeutic use), Nelfinavir (therapeutic use), Oligopeptides (therapeutic use), Pyridines (therapeutic use), Randomized Controlled Trials as Topic, Zidovudine (adverse effects), Zidovudine (therapeutic use).
- MESH :
- chemical , adverse effects : Anti-HIV Agents, Lamivudine, Zidovudine.
- drug therapy : Acquired Immunodeficiency Syndrome, HIV Infections.
- chemical , therapeutic use : Anti-HIV Agents, Benzoxazines, Dideoxynucleosides, Lamivudine, Nelfinavir, Oligopeptides, Pyridines, Zidovudine.
- chemical : Atazanavir Sulfate, Drug Combinations, Humans, Randomized Controlled Trials as Topic.
Abstract
UNAIDS estimates that 34 million people are currently living with the human immunodeficiency virus (HIV) worldwide. Currently recommended regimens for initiating HIV treatment consist of either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or ritonavir-boosted protease inhibitor (PI) combined with two nucleoside reverse transcriptase inhibitors (NRTIs). However, there may be some patients for whom NNRTIs and PIs may not be appropriate. This is an update of the review published in the Cochrane Library Issue 3, 2009.
DOI: 10.1002/14651858.CD005481.pub3
PubMed: 23543540
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001119
- to stream PubMed, to step Curation: 001119
- to stream PubMed, to step Checkpoint: 001119
- to stream Ncbi, to step Merge: 001E16
- to stream Ncbi, to step Curation: 001E16
- to stream Ncbi, to step Checkpoint: 001E16
Links to Exploration step
pubmed:23543540Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.</title><author><name sortKey="Shey, Muki S" sort="Shey, Muki S" uniqKey="Shey M" first="Muki S" last="Shey">Muki S. Shey</name><affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of Kwazulu-Natal, Durban, South Africa. shehushey@yahoo.fr.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of Kwazulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Kongnyuy, Eugene J" sort="Kongnyuy, Eugene J" uniqKey="Kongnyuy E" first="Eugene J" last="Kongnyuy">Eugene J. Kongnyuy</name></author><author><name sortKey="Alobwede, Samuel M" sort="Alobwede, Samuel M" uniqKey="Alobwede S" first="Samuel M" last="Alobwede">Samuel M. Alobwede</name></author><author><name sortKey="Wiysonge, Charles Shey" sort="Wiysonge, Charles Shey" uniqKey="Wiysonge C" first="Charles Shey" last="Wiysonge">Charles Shey Wiysonge</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23543540</idno><idno type="pmid">23543540</idno><idno type="doi">10.1002/14651858.CD005481.pub3</idno><idno type="wicri:Area/PubMed/Corpus">001119</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001119</idno><idno type="wicri:Area/PubMed/Curation">001119</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001119</idno><idno type="wicri:Area/PubMed/Checkpoint">001119</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001119</idno><idno type="wicri:Area/Ncbi/Merge">001E16</idno><idno type="wicri:Area/Ncbi/Curation">001E16</idno><idno type="wicri:Area/Ncbi/Checkpoint">001E16</idno><idno type="wicri:Area/Main/Merge">002A28</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.</title><author><name sortKey="Shey, Muki S" sort="Shey, Muki S" uniqKey="Shey M" first="Muki S" last="Shey">Muki S. Shey</name><affiliation wicri:level="1"><nlm:affiliation>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of Kwazulu-Natal, Durban, South Africa. shehushey@yahoo.fr.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of Kwazulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Kongnyuy, Eugene J" sort="Kongnyuy, Eugene J" uniqKey="Kongnyuy E" first="Eugene J" last="Kongnyuy">Eugene J. Kongnyuy</name></author><author><name sortKey="Alobwede, Samuel M" sort="Alobwede, Samuel M" uniqKey="Alobwede S" first="Samuel M" last="Alobwede">Samuel M. Alobwede</name></author><author><name sortKey="Wiysonge, Charles Shey" sort="Wiysonge, Charles Shey" uniqKey="Wiysonge C" first="Charles Shey" last="Wiysonge">Charles Shey Wiysonge</name></author></analytic><series><title level="j">The Cochrane database of systematic reviews</title><idno type="eISSN">1469-493X</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acquired Immunodeficiency Syndrome (drug therapy)</term><term>Anti-HIV Agents (adverse effects)</term><term>Anti-HIV Agents (therapeutic use)</term><term>Atazanavir Sulfate</term><term>Benzoxazines (therapeutic use)</term><term>Dideoxynucleosides (therapeutic use)</term><term>Drug Combinations</term><term>HIV Infections (drug therapy)</term><term>Humans</term><term>Lamivudine (adverse effects)</term><term>Lamivudine (therapeutic use)</term><term>Nelfinavir (therapeutic use)</term><term>Oligopeptides (therapeutic use)</term><term>Pyridines (therapeutic use)</term><term>Randomized Controlled Trials as Topic</term><term>Zidovudine (adverse effects)</term><term>Zidovudine (therapeutic use)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Agents antiVIH (effets indésirables)</term><term>Agents antiVIH (usage thérapeutique)</term><term>Association médicamenteuse</term><term>Benzoxazines (usage thérapeutique)</term><term>Didéoxynucléosides (usage thérapeutique)</term><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Infections à VIH (traitement médicamenteux)</term><term>Lamivudine (effets indésirables)</term><term>Lamivudine (usage thérapeutique)</term><term>Nelfinavir (usage thérapeutique)</term><term>Oligopeptides (usage thérapeutique)</term><term>Pyridines (usage thérapeutique)</term><term>Sulfate d'atazanavir</term><term>Syndrome d'immunodéficience acquise (traitement médicamenteux)</term><term>Zidovudine (effets indésirables)</term><term>Zidovudine (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-HIV Agents</term><term>Lamivudine</term><term>Zidovudine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Acquired Immunodeficiency Syndrome</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Agents antiVIH</term><term>Lamivudine</term><term>Zidovudine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-HIV Agents</term><term>Benzoxazines</term><term>Dideoxynucleosides</term><term>Lamivudine</term><term>Nelfinavir</term><term>Oligopeptides</term><term>Pyridines</term><term>Zidovudine</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term><term>Syndrome d'immunodéficience acquise</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Agents antiVIH</term><term>Benzoxazines</term><term>Didéoxynucléosides</term><term>Lamivudine</term><term>Nelfinavir</term><term>Oligopeptides</term><term>Pyridines</term><term>Zidovudine</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Atazanavir Sulfate</term><term>Drug Combinations</term><term>Humans</term><term>Randomized Controlled Trials as Topic</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association médicamenteuse</term><term>Essais contrôlés randomisés comme sujet</term><term>Humains</term><term>Sulfate d'atazanavir</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">UNAIDS estimates that 34 million people are currently living with the human immunodeficiency virus (HIV) worldwide. Currently recommended regimens for initiating HIV treatment consist of either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or ritonavir-boosted protease inhibitor (PI) combined with two nucleoside reverse transcriptase inhibitors (NRTIs). However, there may be some patients for whom NNRTIs and PIs may not be appropriate. This is an update of the review published in the Cochrane Library Issue 3, 2009.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A28 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 002A28 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:23543540
|texte= Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:23543540" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |